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Summary The cytoplasmic domain of cadherins is known to associate with the intracellular proteins, catenins, which link cadherins to the
actin-based cytoskeleton. In this study, we immunohistochemically investigated the expression of f-catenin as well as E-cadherin and
a-catenin in 86 human colorectal cancers, and we analysed their coexpression pattern and relationship to clinicopathological factors. In
cancerous tissues, the frequency of reduced expression of ,B-catenin (28 of 86, 33%) was similar to that of E-cadherin (19 of 86, 22%), but
less than that of a-catenin (47 of 86, 55%). All three molecules were expressed strongly, as was the normal epithelium, in 36 cases (42%),
whereas the rest (50 cases, 58%) showed reduction in one of the molecules. The reduction of ,B-catenin expression was significantly
correlated with dedifferentiation, Duke's stage, lymph node metastasis and liver metastasis. Next, we examined tyrosine phosphorylation in
the protein complex immunoprecipitated with E- cadherin, as E-cadherin function is down-regulated by receptor-type tyrosine kinase in vitro.
It was of interest that up-regulation of tyrosine phosphorylation of ,B-catenin was more frequently observed in cancerous tissues than in the
matching normal mucosa.
These results suggest that ,B-catenin may have important regulatory roles within an E-cadherin-mediated adhesion system in human
colorectal cancers.
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Cadherins are calcium dependent, homotypic cell-cell adhesion
molecules that play an important role in the organization and
maintenance oftissue structure (Takeichi, 1977, 1991). As detach-
ment of cell-cell adhesion appears indispensable for cancer inva-
sion and metastasis, this cadherin-mediated cell-cell adhesion
system in cancers has been investigated. We have previously
shown that E-cadherin expression in cancers is frequently
impaired and is inversely correlated with the invasive behaviourof
human cancers (Shiozaki et al, 1991; Oka et al, 1992, 1993).
A group ofcatenins, which couple the cadherins with the micro-
filaments of the cytoskeleton, is essential to the functions of E-
cadherin (Ozawa et al, 1989; Nagafuchi et al, 1991; Tsukita et al,
1992). Deletion of the a-catenin gene, which results in decline of
intercellular adhesion, has been found in PC-9 and PC-3 cancer
cell lines in vitro (Shimoyama et al, 1992; Morton et al, 1993). In
addition, we have reported that a-catenin is frequently decreased
in cancers in vivo, suggesting that not only E-cadherin but also a-
catenin play an important role in cancer invasion and metastasis
(Kadowaki et al, 1994; Shiozaki et al, 1994; Takayama et al, 1994).
Another member of the catenin family, f-catenin (95 kDa), is
considered to mediate interaction between E-cadherin and a-
catenin, as ,B-catenin binds with both the cytoplasmic domain ofE-
cadherin and the amino terminal domain of a-catenin. However,
E-cadherin cannot bind directly to ax-catenin (Aberle et al, 1994).
Mutated f-catenin causes impaired intercellular adhesion in
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HSC-39 cells, in spite ofthe existence ofE-cadherin (Kawanishi et
al, 1995). Other studies demonstrated that 1-catenin was tyrosine
phosphorylated in a cadherin-catenin complex and that elevation
of tyrosine phosphorylation of f-catenin appears to be associated
with cadherin dysfunction in vitro (Matsuyoshi et al, 1992;
Behrens et al, 1993; Hamaguchi et al, 1993).
Recently, 3-catenin has been proved to play a different role in
embryonic morphogenesis. For example, f-catenin is involved
in axis determination in Xenopus embryos, and Armadillo, a
Drosophila homologue of f-catenin, is essential for establishment
of segment polarity (McCrea et al, 1991). These signals may be
different from cadherin-mediated cell adhesion, as they are
generated by a growth factor, Wnt (or its Drosophila homologue,
Wingless), and require cytosolic f-catenin not bound to E-
cadherin (McCrea et al, 1993; Hinck et al, 1994). In addition, it
was reported recently that the APC (adenomatous polyposis coli)
tumour-suppressor gene product forms a complex with f-catenin,
and disruption of this complex is a crucial step in colorectal
carcinogenesis (Rubinfeld et al, 1993; Su et al, 1993). In conse-
quence, mutation in either APC or f-catenin leads to the accumu-
lation ofcytosolic f-catenin, which binds to T-cell factor (Tcf) and
lymphoid enhancer factor (Lef) transcription factors (Korinek et
al, 1997; Morin et al, 1997; Rubinfeld et al, 1997)
Although we have shown that reduced expression of f-catenin
has been frequently observed in human cancers, its significance in
vivo is quite unknown (Takayama et al, 1996). In this study, we
immunohistochemically investigated the expression of f-catenin
and revealed that reduced expression of f-catenin is significantly
correlated with tumour invasion and metastasis in colorectal
cancer tissues. In addition, we examined the tyrosine phosphoryla-
tion of 3-catenin using immunoprecipitation and Western blot, and
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Figure 1 (A-C) Immunoreactivity of ,B-catenin (A), E-cadherin (B), and a-catenin (C) in normal epithelium. (D-I) Coexpression of f-catenin and E-cadherin in
colorectal cancer. Immunoreactive ,-catenin expression (D, F, H), E-cadherin expression (E, G, I). (D and E) All of the tumour cells express on cell-cell
boundaries in the same way as non-cancerous epithelial cells. This tumour was classified as f-catenin (+)/E-cadherin (+). (F and G) All of cancerous cells
express E-cadherin preserved but f-catenin reduced, classified as j-catenin(±)/E-cadherin (+). (H and 1). All of the tumour cells express homogeneously weak
and variable expression. This tumour was classified as ,1-catenin (±)/E-cadherin(±). Bar 50 ,um (x100)
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Table 1 Relationship between ,B-catenin expression and clinicopathological
features
1-Catenin expression P-value
+ + (,)
Total number of cases 58 (67)a 28 (33)
Histological differentiation
well 31 (84) 6 (16) <0.05
moderately 21 (53) 19 (47) (0.259)
poorly 6 (67) 3 (33)
Dukesb classification
A 18 (95) 1 (5)
B 14 (82) 3 (18) < 0.01
C 18 (53) 16 (47) (0.377)
D 8 (50) 8 (50)
Lymph node metastasis
n(-) 35 (85) 6 (15) < 0.01
n (+) 23 (51) 22 (49) (0.365)
Liver metastasis
H (-) 52 (72) 20 (28) < 0.05
H(+) 6 (43) 8 (57) (0.231)
aNumbers in parentheses are percentages. bA, Limited to mucosa; B,
invasion of serosa; C, lymph nodes metastasis by tumour; D, distant
metastasis; n (-), no regional lymph node metastasis; n (+), regional lymph
node metastasis; H(-), no liver metastasis; H(+), liver metastasis.
we found an increase in P-catenin phosphorylation in cancer cells
compared with normal epithelium. Thus, this is the first study to
thoroughly investigate the role of 3-catenin using in vivo cancer
tissues. We also discuss here the possible implication ofP-catenin
in carcinogenesis and progression.
MATERIAL AND METHODS
Patients
Eighty-six patients with colorectal cancer who underwent surgery
at the Second Department Surgery, Osaka University, were investi-
gated in this study. None of them received anti-cancer therapy
preoperatively. Samples for immunohistochemistry were taken
from representative cancerous lesions, including adjacent non-
cancerous mucosa. Samples for Western blotting and immunopre-
cipitation were also obtained from the tumour and normal mucosa,
avoiding contamination from the underlying connective tissues.
They were frozen in liquid nitrogen for less than 1 h after surgical
resection.
Antibodies
The following antibodies were used in this study: mouse mono-
clonal antibody (MAb) against human E-cadherin (HECD-1)
purchased from Takara Shuzo (Shiga, Japan), rat MAb against a-
catenin (oc-18) provided by A Nagafuchi. The rabbit polyclonal
antibody against P-catenin was raised by immunization with
synthetic peptides located in the COOH-terminal of 14 amino
acids of,-catenin conjugated with a keyhole limpet haemocyanine
(KLH), as described previously (Shibamoto et al, 1995). A mouse
MAb against phosphotyrosine (PY-20) was purchased from ICN
Pharmaceuticals (Irvine, CA, USA).
Immunohistochemistry
The fresh tissue samples were embedded in an optimal cutting
temperature (OCT) compound (Miles Laboratory, IL, USA)
and immediately frozen using a dry-ice acetone. The avidin-
biotin-peroxidase complex (ABC) technique was used for
immunohistochemical staining. In brief, 4-gm-thick frozen
sections were made by a cryostat, fixed with 3.6% paraformalde-
hyde in 0.1 M phosphate buffer (pH 7.4), treated with 1% hydrogen
peroxide in methanol for 30 min to inhibit the endogenous peroxi-
dase and were washed with 0.01 M pH 7.2 Tris-buffer (TBS). Non-
specific binding was blocked with blocking buffer (10 mM Tris,
pH 7.2, 150 mm sodium chloride, 3% normal horse serum) for 1 h
at room temperature. Then the sections were incubated with the
primary antibodies (5 gg ml' for E-cadherin, 10 gg ml for
a-catenin and 2 gg ml for 3-catenin) at 4°C overnight. After
washing twice with TBS for 10 min, biotinylated secondary anti-
body and ABC reagent (Vectastain ABC kit, Vector, Burlingame,
USA) were treated following the manufacturer's instructions. The
colour was developed with diaminobendizine supplemented with
0.02% hydrogen peroxide for 4 min, and counterstaining was
performed with Meyer's haematoxylin (Chroma-Gesellschaft,
Schmid, Stuttgart, Germany).
A negative control study for immunoreactivity was performed
with 10 gg mll pre-immune IgG from mouse, rat and rabbit.
Evaluation of immunostaining
In cancerous tissues, the intensity of 3-catenin, E-cadherin and a-
catenin was evaluated compared with normal epithelial cells in the
same section as an internal positive control. As we did not observe
protein overexpression of any of these three molecules, their
expression was classified as follows. When the intensity oftumour
cells was equal to the normal epithelial cells, the expression ofthe
tumour cells was evaluated as being preserved (+). When the
intensity of staining was homogeneously weak or variable, the
expression of the tumour cells was evaluated as being reduced (±)
(Shibamoto et al, 1995).
Histological findings and statistics
A consecutive section from each specimen was stained with
haematoxylin and eosin for histological evaluation. The clinico-
pathological stage was classified according to the modified Duke's
classification (Dukes, 1932; Dukes and Bussey, 1958; Enker et al,
1979). The correlation between 3-catenin expression and clinico-
pathological features was evaluated using both the Spearman rank
correlation coefficient and Fisher's exact test. P < 0.05 was
considered as being statistically significant.
Immunoblot analysis
The tumour and normal mucosa were homogenized in a lysis
buffer (50 mM Tris-HCl pH 7.5, 1% Nonidet P-40, 0.1% sodium
deoxycholate, 2 mm calcium chloride) and clarified by centrifuga-
tion. Then, protein concentration was determined with the
Bradford protein assay kit (Bio-Rad, CA, USA). Fifty milligrams
of protein sample was mixed with the same amount of loading
buffer (20% glycerol, 4.6% sodium dodecyl sulphate (SDS),
125 mm Tris-HCl pH 6.8). After boiling for 5 min in the presence
of 2-mercaptoethanol, the lysate was separated by 7.5%
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SDS-polyacrylamide gels and transferred to Immobilon
polyvinylidene difluoride (PVDF) membranes (Millipore,
Bedford, MA, USA). After blocking with 5% skimmed milk,
or 1% bovine serum albumin (BSA) for phosphotyrosine, the
membranes were incubated with the appropriate primary anti-
bodies for 2 h at room temperature. The filters were washed and
incubated with the appropriate alkaline phosphatase-conjugated
secondary antibodies (Promega, Madison, WI, USA) and devel-
oped with the ProtoBlot NBT and BCIP Color Development
System (Promega, Madison, WI, USA).
Immunoprecipitation
One hundred milligrams of tumour tissues and matching normal
mucosa were homogenized in 1.0 ml of extraction buffer (0.5%
Nonidet P-40, 0.1% SDS, 2 mm phenylmethylsulphonyl fluoride,
2 mm calcium chloride, 1 mm sodium orthovanadate, 3 mM
hydrogen peroxide, 2 jg ofleupeptin, 2 jg ofpepstatin A, 1 ,ug of
aprotinin in 50 mM Tris-buffer saline pH 7.4) and centrifuged at
15 000 r.p.m. for 20 min at 4°C. Two hundred micrograms oftotal
cell lysate were preabsorbed by incubation with 50 ,ul ofprotein A
sepharose (Pharmacia LKB Biotechnology, Uppsala, Sweden) for
30 min. The supernatant was mixed with 4 ,ug ofHECD-1 or 4 ,ug
of 3-catenin for 2 h and then incubated with the protein A
sepharose for 2 h. The beads were collected by centrifugation,
washed five times with the extraction buffer, then suspended in
200,ul of the loading buffer (20% glycerol, 4.6% SDS, 125 mM
Tris-HCI pH 6.8) with 5% 2-mercaptoethanol and boiled for
5 min. The released materials were analysed by immunoblotting.
Analysis of tyrosine phosphorylation of P-catenin
Beta-catenin and its binding proteins were immunoprecipitated
using anti-p-catenin antibody. Half of them were immunoblotted
with anti-phosphotyrosine antibody and the other half with anti-5-
catenin antibody. The density of each band on the Western blotting
was determined by densitometric scanning using Image Scanning
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(Molecular Dynamics, Sunnyvale, CA, USA). The tyrosine phos-
phorylation index of P-catenin was calculated by dividing the
density of the 95 kDa band in the phosphotyrosine immunoblot,
which was supposed to be tyrosine phosphorylated 3-catenin, by
that at the same position on the P-catenin immunoblot. Subsequent
data are presented as the ratio ofthe tyrosine phosphorylation index
ofP-catenin between the tumour and the matching normal mucosa.
RESULTS
Immunostaining of 0--catenin and its correlation with
clinicopathological factors
The normal large bowel epithelium strongly expressed 3-catenin,
E-cadherin and a-catenin at the cell-cell boundaries without
exception. In P-catenin(+) tumours, f-catenin was similarly
expressed at the cell-cell boundaries. On the other hand, ,B-
catenin(±) tumours showed obscure or diffuse expression in the
cytoplasm (Figure 1).
According to our criteria, 58 ofthe colorectal tumours were clas-
sified as P-catenin(+) (58 of 86, 67%) and 28 tumours were classi-
fied as P-catenin(±) (28 of86, 33%). Table 1 shows the relationship
between P-catenin expression and the clinicopathological factors.
The frequency of 1-catenin(+) in the well-differentiated type (84%,
31 of 37) was higher than in the moderately differentiated (53%, 21
of40) or in the poorly differentiated type (67%, six of nine). Thus,
there was a significant positive correlation between the reduced P-
catenin expression and tumour dedifferentiation. On the basis of
Duke's staging, 5% (1 of 19), 18% (3 of 17), 47% (16 of 34) and
50% (8 of 16) ofthe P-catenin (±) tumours were Duke's stage A, B,
C and D respectively. Thus, the reduced expression(±) of f-catenin
was observed more frequently in advanced tumours. Regarding
lymph node metastasis, the frequency of reduced expression of P-
catenin was found more frequently (49%, 22 of45) in patients with
metastasis than in those without (15%, 6 of41). In patients with liver
metastasis, the frequency of 1-catenin(±) was significantly higher
(57%, 8 of 14) than in those without metastasis (28%, 20 of72).
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Figure 2 Immunoblot analysis of E-cadherin (A), a-catenin (B) and 3-catenin (C). Lane 1, normal epithelium; lane 2, colorectal cancer classified as preserved
expression type(+); lane 3, colorectal cancer classified as reduced expression type (±). The molecular weights of 125 kDa, 102 kDa band and 95 kDa
correspond to the complete forms of E-cadherin, a-catenin and 3-catenin respectively
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Immunoblot analysis
To confirm our immunohistochemical staining, immunoblot
anialysis of samples of each staining type was performed. Figure 2
shows the results of immunoblot analysis of the normal mucosa
and ol two representative tumours with a distinct expression
pattern of E-cadherin, oc-catenin and P-catenin. The bands were
revealed at molecular weights of 124 kDa. 102 kDa and 95 kDa,
which correspond to the complete form of E-cadherin, uX-catenin
and f-catenin molecules respectively; the intensity of the bands
correlates with the results of the semiquantitive immunohisto-
chemical evaluation of these molecules.
Correlation between E-cadherin/I-catenin/u-catenin
expression patterns and metastasis
3-Cateinin has been repor-ted to form a complex with cadherini anid
u-catenin, and this binding is necessary for complete cell adhesion
mediated by cadherin. Therefore, we immunohistochemically
investigated not only the expression of 3-catenin but also that of
E-cadherin and ax-catenin.
The coexpression pattern of these three molecules is summa-
rized in Table 2. Expression of E-cadherin and u-catenin was
reduced in 19 tumours and 47 tumours respectively. The frequen-
cies of E-cadherin(+) (22%) and P-catenin(+) (33%) were similar,
but the reduction of (x-catenin (55%) was more frequent than that
of the others. As the assembly of these three molecules has been
recently revealed, we designed the coexpression pattern in the
order of E-cadherin-S-catenin- a-catenini. Thirty-six tumours
Table 2 Coexpression pattern of E-cadherin/0-catenin/(Y-catenin
E-Cadherin 3-Catenin a-Catenin Cases
nf(%)
+ + + 36 (42)
+ + + 16 (19)
+ + ~ +13 (15)
+ + + 12 (14)
+ + + 6 (7)
+ + + 3 (3)
Total 86 (100)
(42%) had preserved expression of all three molecules, while a
reduction in any of these molecules was observed in the remaining
50 tumours (58%/c). Interestingly. except for three cases of E-
cad(+)/4-cat(+)/ux-cat(+). the disorders were always accompanied
with the reduction of oc-catenin [E-cad(+)/f-cat(+)/Ai-cat(+) in
16 cases; E-cad(±)/4-cat(±)/(x-cat(+) in 13 cases; E-cad(+)/4-
cat(+)/(x-cat(+) in 12 cases; E-cad(+)/j-cat(+)/Ux-cat(±) in six
cases]. and no tumours had other patterns, including E-cad(+)/f-
cat(±)/oc-cat(+) or E-cad(+)/4-cat(+)/ox-cat(+). Figure 3 shows the
relationship between the coexpression pattern and the frequency of
Duke's stages C and D, which are representative of metastasis. The
frequency of metastasis in abnormal coexpression patterns (50 of
86. 76%), which have a reduced expression in E-cadherin. f-
catenin or uc-catenin. was significantly higher than that in normal
coexpression patterns (36 of 86. 33%). which preserved all ofthem
(Figure 3A). In addition, we compared the frequency of metastasis
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Figure 3 The relationship between the coexpression pattern and the frequency of Duke's C and D stages, which are representative of metastasis. Duke's A
and B stages, no metastasis; Duke's C and D stages, regional lymph nodes and/or distant metastasis. (A) The relationship between normal and abnormal
coexpression patterns. Normal type, preserved expression of E-cadherin, (-catenin and cx-catenin; abnormal type, reduction in any of these molecules.
(B) Comparison of the frequency of metastasis among the abnormal coexpression patterns
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Figure 4 Immunoblot analysis of ax-catenin (A), ,B-catenin (B) after immunoprecipitation using anti-E-cadherin antibody (HECD-1). Lane 1 and 2,
immunoprecipitated by normal mouse IgGl as negative control, normal large bowel epithelium and colorectal cancer respectively. Lane 3, normal mucosa;
lanes 4 and 5, colorectal cancers evaluated as preserved (+) and reduced (+) type respectively. Arrows indicate full-sized a-catenin (102 kDa) and ,B-catenin
(95 kDa) molecules respectively. The lower-molecular-mass bands are considered to be derived from immunoglobulin
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Figure 5 (A) Immunoblot analysis of phosphotyrosine after immunoprecipitation using anti-E-cadherin antibody (HECD-1). Lanes 1 and 2, immunoprecipitated
by normal mouse IgGl as negative control, normal large-bowel epithelium and colorectal cancer respectively. Lane 3, normal mucosa; lane 4, colorectal cancer.
Arrows indicate a 95 kDa band, which is identical to ,-catenin. (B) Immunoblot analysis of l-catenin (lanes 1 and 2) and phosphotyrosine (lanes 3 and 4) after
immunoprecipitation using anti-Il-catenin antibody. Lanes 1 and 3, normal large bowel epithelium; lanes 2 and 4, colorectal cancer
among the groups with abnormal coexpression patterns (Figure
3B). This frequency of metastasis was similar (ranging from
67-92%), although it was a little higher in the tumours with E-
cad(±)/P-cat(±)/oc-cat(±) than in other patterns.
Tyrosine phosphorylation in immunoprecipitates with
E-cadherin
The protein complex of E-cadherin, f-catenin and a-catenin was
observed not only in the normal epithelium but also in the repre-
sentative E-cadherin(+) tumours (Figure 4). In addition, we identi-
fied thaty-catenin also formed a complex with E-cadherin (data not
shown). As tyrosine phosphorylation of this complex caused a
decline of E-cadherin-mediated adhesion in vivo, we examined it
in colorectal cancer tissues and matching normal mucosa. Fourteen
tumours, including 13 E-cad(+) and one E-cad(±), and their
matching normal mucosa were used for immunoprecipitation. In
the immunoprecipitates with E-cadherin, tyrosine phosphorylation
at the 95-kDa band, which is identical to ,B-catenin, was observed,
while tyrosine phosphorylation ofE-cadherin or a-catenin was not
detectable. Interestingly, tyrosine phosphorylation at the 95 kDa
band was recognized not only in cancerous tissues but also in the
normal mucosa (Figure 5). The tyrosine phosphorylation index of
1-catenin were calculated by anti-1-catenin and anti-phosphotyro-
sine immunoblots with the f-catenin immunoprecipitant. The tyro-
sine phosphorylation index ratios between the tumours and the
matching normal mucosa are summarized in Table 3. This ratio has
been proved to be reproducible in preliminary experiments (stan-
dard deviations were 0.140 and 0.151 in triplicate experiments
using two different tissue samples) (data not shown). The tyrosine
phosphorylation index of f-catenin in cancerous tissues was
similar to that in the normal mucosa in 3 of 14 (21%) cases (within
2 s.d.) and higher in 11 (79%) of 14 cases, hence the difference
between the tumour and the normal mucosa was statistically signif-
icant (P < 0.05). However, no significant correlation was found
between clinical staging and the tumour-normal ratios of the tyro-
sine phosphorylation index ofP-catenin.
DISCUSSION
We and other investigators have demonstrated that the decline of
the E-cadherin cell adhesion molecule directly resulted in tumour
invasion in vivo, and this has a strong correlation with tumour
invasion and metastasis in human cancer tissues (Shiozaki et al,
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Table 3 The relationship between clinical findings and tyrosine phosphorylation levels of f-catenin
Case Histological Duke's Lymph node Liver E-Cadherin j-catenin a-Catenin Tyrosine phosphorylation
grade stage metastasis metastasis of I-catenin
T/N ratio
1 1 B - - + + + 0.86
2 1 B - - + + + 1.01
3 2 B - - + + + 1.13
4 2 D - + + + + 1.31
5 1 D + + + + + 1.35
6 1 A - - + + + 1.38
7 2 D - + + + + 1.38
8 1 A - - + + + 1.46
9 3 C + - + + + 1.67
10 1 C + - + + + 1.75
11 1 A - - + + + 1.94
12 3 B - - + + + 2.49
13 2 B - - + + + 2.95
14 2 D + + + + + 3.30
1991; Oka et al, 1992, 1993). E-cadherin is known to form a
complex with several cytoplasmic proteins, including a-, 1-, y-
catenins and p120, and to be connected finally to the actin fila-
ments (Ozawa et al, 1989; Shibamoto et al, 1995). The lack of
normal a-catenin has been observed in the cultured cell lines PC 9
and PC 3, and it caused dysfunction ofE-cadherin-mediated adhe-
sion (Shimoyama et al, 1992; Morton et al, 1993). In addition, we
have shown that the reduced expression of a-catenin in human
cancer tissues is frequent and is strongly associated with tumour
invasion and metastasis (Kadowaki et al, 1994; Shiozaki et al,
1994; Takayama etal, 1994). Thus, notonly E-cadherin but also a-
catenin are key molecules that control tumour invasion and metas-
tasis through disturbance ofintercellular adhesions.
For a long time, the role of ,B-catenin in the cadherin adhesion
system was not understood. However, the assembly of cadherin
and associated proteins has recently been elucidated. In the inter-
cellular adherencejunction, the cytoplasmic domain ofcadherin is
bound to ,B-catenin, which is also bound to the amino terminal of
a-catenin at another site (Aberle et al, 1994; Nagafuchi et al,
1994). Then, the carboxyl terminal of a-catenin is directly bound
to actin filament or is indirectly bound to actin through a-actinin
(Knudsen et al, 1995). 1-Catenin, as well as a-catenin, are indis-
pensable for cadherin-mediated cell adhesion, as mutation of 1-
catenin in HSC-39 and -40 human gastric cancer cells causes
impaired E-cadherin function (Oyama et al, 1994; Kawanishi et al,
1995). However, mutation of the 1-catenin gene has not been
found in human cancer tissues but only in cultured cell lines
(Candidus et al, 1996). Nevertheless, we have often observed
reduced protein expression by immunohistochemistry and
immunoblotting in human cancer tissues. This might imply that
the reduced protein expression of 1-catenin is due to a transcrip-
tional or post-transcriptional event in vivo. In this study, using
human colon cancer specimens obtained by surgery, we tried to
elucidate the clinical significance of 1-catenin expression and to
compare it with E-cadherin and a-catenin expression.
Reduced expression of ,B-catenin was observed in 33% (28 of
86) of colon cancer tissues, and this had a significant correlation
with dedifferentiation, lymph node metastasis, liver metastasis and
advanced stages in Duke's classification. Disruption of intercel-
lular adhesion is considered to be necessary for all these pheno-
types. Among E-cadherin, 1-catenin and a-catenin, reduced
expression of a-catenin was the most frequent. Previous studies
have shown that a-catenin has to be linked to E-cadherin to
prevent protein degradation, while both E-cadherin and 1-catenin
can exist without forming a protein complex (Shimoyama et al,
1992; Nagafuchi et al, 1994). Therefore, disorder of either E-
cadherin or ,B-catenin might secondarily induce reduction of a-
catenin. The coexpression pattern of these three molecules is
almost compatible with this hypothesis. In our study, 94% of the
tumours (47 of 50) with an abnormal coexpression pattern had a
reduced a-catenin expression alone or with concomitant reduction
in the expression of E-cadherin and/or 13-catenin. However, there
were three exceptional cases; these expressed a-catenin with a
reduction in 1-catenin [E-cad (+), 1-cat (±), a-cat (+)]. In these
cases, y-catenin might have substituted for 1-catenin to form a
complex with E-cadherin and a-catenin. We also found six
tumours with E-cad (±), ,3-cat (+), a-cat (±). Beta-catenin in these
tumours is not involved in E-cadherin-mediated intercellular adhe-
sion. Hence, it is of interest to elucidate the function of 1-catenin
in these tumours.
Recently, it was revealed that ,B-catenin is involved not only in
the cadherin cell adhesion system but also in the growth signal
pathway. The signals generated by Wingless or its vertebral homo-
logue Wnt, which is essential for embryonal organization, induce
protein expression of1-catenin. The role of1-catenin downstream
of Wnt seems to be different from that in cadherin-mediated cell
adhesion because this ,B-catenin, induced by Wnt, exists in cytosol
without binding to cadherin (McCrea et al, 1993). Moreover, over-
expression of truncated ,B-catenin, which cannot bind with a-
catenin, has an effect in embryogenesis similar to that of the wild
type of1-catenin or growth signal ofWnt (Funayama et al, 1995).
Wnt also acts as an oncogene in human mammary carcinogenesis
(Kwan et al, 1992). Therefore, it might be ofinterest to investigate
Wnt expression in this type ofcancer.
It has been demonstrated that 1-catenin binds with the APC
tumour-suppressor gene product in the cytoplasm, and this
complex does not include cadherin (Rubinfeld et al, 1995). The
APC gene is mutated in 80% of colorectal cancer cases (Miyoshi
et al, 1992). Interestingly, most mutations occurred at the P-catenin
binding site (Rubinfeld et al, 1995). The wild type of APC has
little effect on the 1-catenin binding with cadherin, but it decreases
the protein content of the cytosolic-free ,B-catenin (Munemitsu et
al, 1995). The function ofAPC as a tumour-suppressor gene might
bind and limit the cytosolic-free 1-catenin. ,B-catenin in this status
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binds to Tcf and Lef transcription factors, which play key roles
downstream ofthe Wingless signal (Korinek et al, 1997; Morin et
al, 1997; Rubinfeld et al, 1997). The association ofAPC mutation
and cytoplasmic j-catenin expression has been studied in
colorectal polyps (Inomata et al, 1996). Further study concerning
cytoplasmic 3-catenin and transcription factors may be required in
the future.
Beside the reduction of protein expression, another disorder of
0-catenin is observed in cancer cells. Tyrosine phosphorylation of
0-catenin is observed in the cell transformed with v-src, and it
counteracts E-cadherin-mediated junctional assembly (Matsuyoshi
et al, 1992; Behrens et al, 1993; Hamaguchi et al, 1993). We
reported a similar effect in oncogenic stimulation through
epidermal growth factor receptor or hepatocyte growth factor
receptor (Shibamoto et al, 1994; Shiozaki et al, 1995). In previous
studies, tyrosine phosphorylation ofP-catenin was considered to be
characteristic of cancer cells. However, in this study, it was
observed in the non-cancerous colon epithelium, although the
amount was less than that in cancer cells.
The amount oftyrosine phosphorylated 0-catenin showed some
diversity among tumours, but there were no significant correla-
tions between tyrosine phosphorylation of 0-catenin and the
clinicopathological factors. Takeda et al (1995) reported that
tyrosine phosphorylation of f-catenin is not required for the
dysfunction ofcadherin-based cell adhesion in the introduction of
the v-src model. On the other hand, Kinch et al (1995) reported
that the elevation of tyrosine-phosphorylated 3-catenin attenuated
the connection between E-cadherin and 3-catenin. Thus, although
tyrosine phosphorylation of 3-catenin is parallel to the decline
of cadherin-mediated adhesion, the direct interaction is still
controversial, and the mechanism is still not well understood.
Further studies are required to understand the clinical significance
oftyrosine-phosphorylated 3-catenin in vivo.
In conclusion, our findings suggest that the frequent reduction
of a- and 3-catenin, which causes dysfunction in the E-cadherin-
mediated adhesion complex, may play a critical role in cancer
invasion and metastasis. In addition, tyrosine phosphorylation of
3-catenin may participate in regulation of the cadherin-catenin
complex in vivo. These results suggest that 3-catenin may have
important regulatory roles in the E-cadherin-mediated adhesion
system in human colorectal cancers.
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